Shares of Becton Dickinson (BDX) surged 5.03% during intraday trading on Thursday, fueled by a stronger-than-expected fiscal third-quarter earnings report. The medical technology company’s results beat Wall Street estimates on both the top and bottom lines, driven by robust demand for its drug-delivery devices and surgical equipment.

BD reported an adjusted profit of $3.23 per share for the quarter, surpassing the consensus estimate of $3.14. Revenue rose 5.4% to $4.98 billion, also exceeding analyst expectations of $4.89 billion. Segment performance was led by the Interventional unit, which saw revenue increase 6.4% to $1.41 billion, and the Connected Care segment, which grew 4.9% to $1.22 billion.

Adding to the positive momentum, the company raised the lower end of its full-year adjusted earnings per share guidance to a range of $12.62 to $12.72, up from its prior forecast of $12.52 to $12.72. Management also indicated that revenue growth is now expected to be toward the high end of its low single-digit range. Executives cited strong momentum across key growth platforms and disciplined execution as key factors behind the improved outlook.